Highest-materiality recent filing
FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's
VY1706 targets intra- and extracellular tau; IND cleared by FDA on June 1, 2026.
Voyager Q1 net loss $27.9M, cash $172M into 2028; VY1706 tau gene therapy on track for H2 dosing
Net loss $27.9M (Q1 2026) vs $31.0M (Q1 2025); revenue $2.6M down from $6.5M due to lower collaboration revenue.
Voyager Therapeutics CFO Nathan Jorgensen resigns; Robin Swartz named PFO, Amy Quinlan PAO
CFO Nathan Jorgensen, Ph.D. resigns effective May 8, 2026, to pursue new opportunity; no disagreement with company.
Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026
Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.
Chief Medical Officer Toby Ferguson resigns; CEO Sandrock takes over clinical leadership
Toby Ferguson, M.D., Ph.D., resigned as CMO effective Feb 20, 2026, to pursue a new opportunity.
Biogen's BIIB080 Phase II data expected mid-2026; Voyager's VY1706 gene therapy first-in-human in H2 2026.
Voyager Q3 net loss widens to $27.9M; cash runway into 2028; NeuroShuttle platform launched
Net loss of $27.9M (vs $9.0M in Q3 2024); collaboration revenue fell to $13.4M from $24.6M.
Company presented at Citi's 2025 Biopharma Back to School Conference on September 2, 2025.
Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028
Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.
Voyager stockholders approve 2025 stock plans, elect directors at annual meeting
Approved 2025 Stock Incentive Plan: 28.6M for, 11.3M against, 8.5M broker non-votes.
Voyager Q1 2025 net loss $31.0M, revenue down 67% YoY; cash $295M into mid-2027
Net loss $31.0M vs $11.3M YoY; collaboration revenue $6.5M vs $19.5M YoY (−67%).
Voyager Therapeutics Q4 2024 net loss $34.5M; tau gene therapy VY1706 IND filing planned for 2026
Net loss $34.5M in Q4 2024 vs net income $56.4M in Q4 2023; full year net loss $65.0M vs income $132.3M.
Voyager delays SOD1 ALS IND filing; switches payload after NHP data; cash runway to mid-2027
VY9323 IND/CTA filing no longer expected mid-2025 due to need for alternate payload after 3-month NHP data.
Voyager Q3 net loss narrows to $9.0M; new Novartis capsid license; VY7523 SAD data H1 2025
Q3 collaboration revenue $24.6M (up from $4.6M YoY); net loss $9.0M vs $25.9M.
Voyager grants Novartis license to capsid for gene therapy; $15M upfront, up to $305M milestones
Novartis receives exclusive license to a capsid from Voyager's TRACER platform for a single gene target.
Voyager Q2 net loss narrows to $10.1M; cash $371M; anti-tau trial underway, data H1 2025
Q2 collaboration revenue $29.6M (vs $4.9M YoY); net loss $10.1M vs $22.2M loss a year earlier.
Voyager Therapeutics appoints Nathan Jorgensen as CFO effective July 8, 2024
Jorgensen, 47, previously CFO of Vor Biopharma; will report to CEO Alfred Sandrock.
Voyager stockholders elect three Class III directors, approve say-on-pay, ratify auditor
Michael Higgins, Jude Onyia, and Nancy Vitale elected Class III directors until 2027.
First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.
Voyager Q1 net loss $11.3M; IND cleared for VY-TAU01; cash $400M to 2027
Net loss of $11.3M vs net income of $124.0M in Q1 2023; collaboration revenue $19.5M down from $150.5M.
CFO Peter Pfreundschuh resigns effective April 12, 2024; remains as Senior Financial Advisor until May 5, 2024.
Voyager Therapeutics names Toby Ferguson as Chief Medical Officer
Employment starts March 25, 2024; base salary $485,000, target bonus 40%.
Voyager Therapeutics reports Q4 net income $56.4M, pro-forma cash $431M, pipeline milestones
Q4 collaboration revenue $90.1M (vs -$1.6M YoY), net income $56.4M (vs loss $23.6M).
On June 11, 2024, Voyager Therapeutics, Inc. (the “Company”) and Nathan Jorgensen entered into an employment agreement (the “Jorgensen Agreement”), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024
Max materiality 0.75 · Median 0.60 · Most common event earnings